Drug intelligence / Profile preview

TPE-1

Development stage: Phase 3
Lead developer: Taipei City Hospital
Modality: Small Molecules
Administration: Oral

Overview

TPE-1 is a compound herbal formula developed by Taipei City Hospital as a traditional Chinese medicine (TCM) decoction. It is specifically designed to treat leukopenia (low white blood cell count) and cancer-related fatigue in breast cancer patients undergoing radiotherapy. Unlike direct anti-cancer agents, TPE-1 functions by invigorating Qi and strengthening the body's resistance (immunity) according to TCM principles. It has been evaluated in a Phase 2/3 clinical trial (NCT01142479) to assess its efficacy and safety in patients who have completed chemotherapy and are receiving radiation treatment.

Other names: Compound Herbal Formula (TPE-1)Chinese herbal medicine decoction

Beyond the preview

Go deeper on TPE-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPE-1.

Explore the full profile